Clinical Trial Update: Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on ELGN-2112 for intestinal malabsorption in preterm infants. The study is currently recruiting to evaluate efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intestinal Malabsorption

Drugs mentioned

• ELGN-2112

Snippet

Sponsor: Elgan Pharma Ltd. | Conditions: Intestinal Malabsorption | Phase 3 | Status: RECRUITING